Krystal Biotech (FRA:4KB) Moat Score: 7/10 (As of Jun. 29, 2026)


FRA:4KB Krystal Biotech Inc FRA:4KB
58 GF Score
Price €326.30
GF Value €262.63
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Krystal Biotech Moat Score?

Krystal Biotech FRA:4KB +4.12% 58 Moat Score is 7 as of Jun. 29, 2026. GuruFocus rates FRA:4KB with a GF Score™ of 58/100 and a GF Value™ of €262.63 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 1,401 Biotechnology companies, Krystal Biotech ranks better than 99.57% on this metric.

Krystal Biotech has the Moat Score of 7, which implies that the company might have Wide Moat - Entry-level wide moat, clearly possessing durable advantages.

Krystal Biotech has Wide Moat: Krystal Biotech possesses a wide moat due to its valuable intellectual property and strong R&D capabilities in gene therapy. It benefits from significant regulatory barriers and exclusive licenses, providing durable competitive advantages in the biotech industry.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Krystal Biotech might have Wide Moat - Entry-level wide moat, clearly possessing durable advantages.

Krystal Biotech  (FRA:4KB) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Krystal Biotech Moat Score Related Terms

FRA:4KB vs TECH, SMMT, ARWR: Moat Score Comparison

For the Biotechnology subindustry, Krystal Biotech's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Krystal Biotech Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Krystal Biotech's Moat Score distribution charts can be found below:

* The bar in red indicates where Krystal Biotech's Moat Score falls into.


FRA:4KB
58GF Score
Krystal Biotech Inc FRA:4KB
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 7 mean?
Krystal Biotech (FRA:4KB) has a Moat Score of 7 as of Jun. 29, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Krystal Biotech ranks #6 out of 1401 companies in the Biotechnology industry, placing it in the top 0.40000000000001%.
Is Krystal Biotech's Moat Score too high?
Krystal Biotech's current Moat Score is 7. The Biotechnology industry median Moat Score is 2.00. Krystal Biotech's value of 7 is 250% above this industry median. Based on the distribution chart, Krystal Biotech ranks #6 out of 1401 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Krystal Biotech has a GF Score™ of 58/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Krystal Biotech's Moat Score compare to TECH and SMMT?
According to the Biotechnology industry distribution chart, Krystal Biotech ranks #6 out of 1401 companies for Moat Score. This places Krystal Biotech in the top 0% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Krystal Biotech's value of 7 is 250% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,401 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Krystal Biotech's current Moat Score of 7 is 250% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Krystal Biotech's current Moat Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Krystal Biotech stock overvalued right now?
Based on GuruFocus' analysis, Krystal Biotech (FRA:4KB) is currently considered Modestly Overvalued. The stock's GF Value™ is €262.63, compared to a current price of €326.30 — trading 24.2% above its estimated fair value. The current Moat Score is 7 and 250% above the Biotechnology industry median of 2.00. Krystal Biotech's overall GF Score™ is 58/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Krystal Biotech (FRA:4KB), the current Moat Score is 7 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Krystal Biotech (FRA:4KB) Overvalued in 2026?

Based on GuruFocus' analysis, Krystal Biotech stock appears to be overvalued. The current stock price of €326.30 is trading 24.2% above its estimated GF Value™ of €262.63. GuruFocus considers Krystal Biotech to be Modestly Overvalued.

Key valuation signals for FRA:4KB:

  • Moat Score: 7
  • GF Value™: €262.63 vs. price of €326.30 (24.2% above fair value)
  • GF Score™: 58/100 with 6 warning signs
  • Industry Position: 250% above the Biotechnology median (#6 of 1401)

No single metric tells the full story. See the FRA:4KB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Krystal Biotech Business Description

Address 2100 Wharton Street, Suite 701, Pittsburgh, PA, USA, 15203
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
58GF Score

Get the complete analysis for FRA:4KB

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€326.30
Price
€262.63
GF Value